Akèy › Degeneresans makile
Etid klinik pou Degeneresans makile ap rekrite nan Etazini
55 etid pou Degeneresans makile ap rekrite patisipan nan sit atravè Etazini.
Vil ki gen plis etid
- Dallas, TX13 etid
- Erie, PA10 etid
- The Woodlands, TX9 etid
- Hagerstown, MD8 etid
- Reno, NV8 etid
- Sacramento, CA8 etid
- Houston, TX7 etid
- Fort Worth, TX7 etid
- Santa Monica, CA7 etid
- Cleveland, OH7 etid
- Austin, TX7 etid
- Carmel, IN7 etid
- Salt Lake City, UT7 etid
- Boston, MA7 etid
- Phoenix, AZ7 etid
- Raleigh, NC6 etid
- Mountain View, CA6 etid
- Nashville, TN6 etid
- Naperville, IL6 etid
- Columbia, SC6 etid
- Cincinnati, OH6 etid
- Washington, DC6 etid
- Philadelphia, PA6 etid
- McAllen, TX6 etid
- Portland, OR6 etid
- San Francisco, CA5 etid
- San Antonio, TX5 etid
- Eugene, OR5 etid
- Orlando, FL5 etid
- Durham, NC5 etid
- Pensacola, FL5 etid
- Fort Lauderdale, FL5 etid
- Lynchburg, VA5 etid
- Syracuse, NY5 etid
- Spokane, WA5 etid
- Tampa, FL5 etid
- Cypress, TX4 etid
- Cary, NC4 etid
- Colorado Springs, CO4 etid
- Sarasota, FL4 etid
Pa eta
- Arizona11 etid
- Colorado7 etid
- Connecticut6 etid
- Florid14 etid
- Georgia6 etid
- Illinois13 etid
- Indiana7 etid
- Kalifòni20 etid
- Maryland11 etid
- Massachusetts14 etid
- Michigan9 etid
- Minnesota5 etid
- Mississippi5 etid
- Missouri5 etid
- Nevada8 etid
- New Jersey7 etid
- New York10 etid
- North Carolina11 etid
- Ohio11 etid
- Oklahoma3 etid
- Oregon9 etid
- Pennsylvania17 etid
- South Carolina8 etid
- Tennessee7 etid
- Texas24 etid
- Utah9 etid
- Virginia7 etid
- Washington8 etid
- Wisconsin6 etid
Etid ki fèk mete ajou
Tèks ofisyèl etid la (Anglè)
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Ap rekriteFaz 2/3
Laj 60 ak plis · Tout sèks · Mizajou Sep 30, 2026 · NCT06635148National Eye Institute Biorepository for Retinal Diseases
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
Laj 2 a 120 · Tout sèks · Mizajou Sep 28, 2026 · NCT01496625A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Ap rekriteFaz 1/2
Laj 55 ak plis · Tout sèks · Mizajou Sep 23, 2026 · NCT07029945Cell Collection to Study Eye Diseases
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
1 Day – 120 Years · Tout sèks · Mizajou Sep 22, 2026 · NCT01432847A Study in Adults With Geographic Atrophy
Ap rekriteFaz 2
Laj 60 ak plis · Tout sèks · Mizajou Sep 21, 2026 · NCT07606365A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
Ap rekriteFaz 2/3
Laj 50 ak plis · Tout sèks · Mizajou Sep 18, 2026 · NCT07440225A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy
Ap rekriteFaz 3
Laj 50 a 85 · Tout sèks · Mizajou Sep 18, 2026 · NCT06541704A Study About the Safety of a Single ASP2020 Eye Injection and if it Helps People With Vision Loss From Stargardt-type Eye Conditions
Ap rekriteFaz 1
Laj 6 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07734064A Phase 2 Study of NT-101 Topical in Patients With Wet AMD
Ap rekriteFaz 2
Laj 50 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT07811726The Effects of Disulfiram (Antabuse®) on Visual Acuity in Patients With Retinal Degeneration
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Sep 16, 2026 · NCT06319872Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD
Ap rekriteFaz 2
Laj 55 ak plis · Tout sèks · Mizajou Sep 10, 2026 · NCT06659445A Non-Interventional Study Observing Short-Term Progression in Geographic Atrophy (GA)
Ap rekriteEtid obsèvasyon
Laj 55 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT07144137Noninvasive Imaging Biomarkers of Treatable Macrovascular Disease in Age-related Macular Degeneration.
Ap rekriteEtid obsèvasyon
Laj 50 a 80 · Tout sèks · Mizajou Sep 3, 2026 · NCT07798323A Study of the Safety and Tolerability of ASP7317 in Senior Adults Who Are Losing Their Clear, Sharp Central Vision Due to Geographic Atrophy Secondary to Dry Age-related Macular Degeneration
Ap rekriteFaz 1
Laj 50 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT03178149A Long-term Follow-up Study to Evaluate SKG0106 in the Treatment of Patients With nAMD
Ap rekriteEtid obsèvasyon
Laj 50 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT06346600Effect of Lutein, Zeaxanthin, and Meso-Zeaxanthin Supplementation on Skin Carotenoid Concentration: A Six-Month, Placebo-Controlled Crossover Study
Ap rekriteVolontè an sante akeyi
Laj 18 ak plis · Tout sèks · Mizajou Sep 1, 2026 · NCT06965426Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration
Ap rekrite
Laj 60 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT06662162SGLT2 Inhibitors in Geographic Atrophy
Ap rekriteFaz 2
Laj 50 ak plis · Tout sèks · Mizajou Aug 26, 2026 · NCT07174687A Study to Learn How Stargardt-type Eye Conditions Progress in Children and Adults
Ap rekriteEtid obsèvasyon
Laj 6 ak plis · Tout sèks · Mizajou Aug 25, 2026 · NCT074255744D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
Ap rekriteFaz 1/2
Laj 50 ak plis · Tout sèks · Mizajou Aug 21, 2026 · NCT05197270A Phase 2 Efficacy and Safety Study of GAL-101, 2% Ophthalmic Solution in Non-foveal Geographic Atrophy Secondary to Non-neovascular AMD
Ap rekriteFaz 2
Laj 55 ak plis · Tout sèks · Mizajou Aug 20, 2026 · NCT06659549Phase 1 Study of C.001 in Retinal Degeneration
Ap rekriteFaz 1
Laj 18 ak plis · Tout sèks · Mizajou Aug 17, 2026 · NCT07594236AMD and Validation Rod-Meditated Dark Adaptation With Everyday Task Performance
Ap rekriteVolontè an sante akeyi
Laj 50 a 89 · Tout sèks · Mizajou Aug 10, 2026 · NCT06619405A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Ap rekriteFaz 2/3
Laj 50 ak plis · Tout sèks · Mizajou Aug 6, 2026 · NCT07496567Intravitreal (IVT) Pozelimab for Geographic Atrophy (GA) in Adult Participants
Ap rekriteFaz 1
Laj 50 ak plis · Tout sèks · Mizajou Aug 5, 2026 · NCT07230834Sous ClinicalTrials.gov, done yo ranmase Oct 1, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.